Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma

Radiotherapy and Oncology

Volumn 50, Issue 2, 1999, Pages 191-197

  Bachaud, Jean Marc ^a   Berthier, Frédéric ^b   Soulié, Michel ^c   Malavaud, Bernard ^c   Plante, Pierre ^c   Rischmann, Pascal ^c   Chevreau, Christine ^a   Daly Schveitzer, Nicolas ^a   Grosclaude, Pascale ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b Registre des Cancers du Tarn   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Radiotherapy; Second cancer; Seminoma; Testicular neoplasms

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; DACTINOMYCIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; DISEASE ASSOCIATION; FOLLOW UP; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER; SEMINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0032940362     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(98)00101-7     Document Type: Article

References (25)

1. Akre O., Ekbom A., Hseih C.C., Tricopoulos D., Adami H.O. Testicular nonseminomatous and seminoma in relation to perinatal characteristics. J. Natl. Cancer Inst. 88:1996;883-889.
2. Bokemeyer C., Schmoll H.J. Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol. 11:1993;1703-1709.
3. Bokemeyer C., Schmoll H.J. Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol. 13:1995;283-292.
4. Breslow NE, Day NE. Rates and rate standardization. In: Breslow NE, Day NE, editors. Statistical methods in cancer research, IARC Sci. Pub. No. 82, Vol. 2. Lyon: Agency for Research on Cancer, 1987.
5. Chao C.K., Lai P.P., Michalski J.M., Perez C.A. Secondary malignancy among seminoma patients treated with adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 4:1995;831-835.
6. Coleman M., Douglas A., Hermon C., Peto J. Cohort study analysis with a fortran computer program. Int. J. Epidemiol. 15:1986;134-137.
7. Einhorn L.H. Radiotherapy in seminoma: more is not better. Int. J. Radiat. Oncol. Biol. Phys. 8:1982;309-310.
8. Fossa S.D., Langmark F., Aass N., Andersen A., Lothe R., Borresen A.L. Second non germ-cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br. J. Cancer. 61:1990;639-643.
9. Hanks G.E., Herring D.F., Kramer S. Pattern of care outcome studies: results of the national practice in seminoma of the testis. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;949-950.
10. Hanks G.E., Peters T., Owen J. Seminoma of the testis: long term beneficial and deleterious results of radiation. Int. J. Radiat. Oncol. Biol. Phys. 24:1993;913-919.
11. Hay J.H., Duncan W., Kerr G.R. Subsequent malignancies in patients irradiated for testicular tumors. Br. J. Radiol. 57:1984;597-602.
12. Heimdal K., Olsson H., Tretli S., Borresen A.-L., Fossa S.D. Risk of cancer in relatives of testicular cancer patients. Br. J. Cancer. 73:1996;970-973.
13. Hellbardt A., Mirimanoff R.O., Obradovic M., Mermillow B., Paunier J.P. The risk of second cancer in patients treated for testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys. 18:1990;1327-1331.
14. Horwich A., Bell J. Mortality and cancer incidence following radiotherapy for seminoma of the testis. Radiother. Oncol. 30:1994;193-198.
15. Jacobsen G.K., Mellemgaard A., Engelholm S.A., Moller H. Increased incidence of sarcoma in patients treated for testicular seminoma. Eur. J. Cancer. 5:1993;664-668.
16. Kaldor J.M., Day N.E., Band P., et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int. J. Cancer. 39:1987;571-585.
17. Li M.C., Whitmore W.F., Golbey R., Grabstald H. Effects of combined drug therapy on metastatic cancer of the testis. J. Am. Med. Assoc. 174:1960;145-153.
18. Moller H., Mellemgaard A., Jacobsen G.K., Pedersen D., Storm H.H. Incidence of second primary cancer following testicular cancer. Eur. J. Cancer. 5:1993;672-676.
19. Oliver R.T.D., Edmonds P.M., Ong J.Y.H., et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 29:1994;3-8.
20. Oliver R.T.D., Oliver J.C. Endocrine hypothesis for declining sperm count and rising testis cancer incidence. Lancet. 346:1996;339-340.
21. Robinson E., Neugut A.I., Wylie P. Clinical aspects of postirradiation sarcomas. J. Natl. Cancer Inst. 80:1988;233-240.
22. Tucker M.A., Coleman C.N., Cox R.S., Varghese A., Rosenberg S.A. Risk of second cancers after treatment for Hodgkin's disease. N. Engl. J. Med. 318:1988;76-81.
23. van der Maase H., Specht L., Jacobsen G.K. Surveillance following orchiectomy for stage I seminoma of the testis. Eur. J. Cancer. 29:1993;1931-1934.
24. van Leeuwen F.E., Stiggelbout A.M., van den Belt-Dusebout A.W., et al. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J. Clin. Oncol. 11:1993;415-424.
25. Westergaard T., Olsen J.H., Frisch M., Kronman M., Neilsen J.W., Melbye M. Cancer risk in fathers and brothers of testicular cancer patients in Denmark; a population-based study. Int. J. Cancer. 66:1996;627-631.